301281SZSE

Legal Opinion of Beijing Deheng (Jinan) Law Firm on Shandong Keyuan Pharmaceutical Co., Ltd.'s 2025 Restricted Stock Incentive Plan Reserved Grant Matters

Keyuan Pharmaceutical Co., Ltd.··9 pages

✨ AI Summary

This legal opinion confirms that Shandong Keyuan Pharmaceutical Co., Ltd. has obtained necessary approvals for its 2025 Restricted Stock Incentive Plan. The plan includes granting 600,000 shares at a price of 14.71 RMB per share to seven eligible participants. The granting date is set for June 1, 2026, and all conditions for the grant have been met in accordance with relevant laws and regulations.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Legal Opinion of Beijing Deheng (Jinan) Law Firm on Shandong Keyuan Pharmaceutical Co., Ltd.'s 2025 Restricted Stock Incentive Plan Reserved Grant Matters

Address: No. 2, Yinfeng Technology Park, 567 Shuntai North Road, High-tech Zone, Jinan, Shandong Province, 250102
Website: www.dehenglaw.com
Phone: (86) 531-8166 3606

Definitions

In this legal opinion, unless otherwise specified, the following terms have the meanings set forth below:

  • "Deheng" or "this firm" refers to Beijing Deheng (Jinan) Law Firm.
  • "Keyuan Pharmaceutical/Listed Company/Company" refers to Shandong Keyuan Pharmaceutical Co., Ltd.
  • "This Incentive Plan/Incentive Plan" refers to the draft of Shandong Keyuan Pharmaceutical Co., Ltd. 2025 Restricted Stock Incentive Plan.
  • "Grant" refers to the reserved grant matters related to the 2025 Restricted Stock Incentive Plan of Shandong Keyuan Pharmaceutical Co., Ltd.
  • "Restricted Stock/Second Category Restricted Stock" refers to the company stock that meets the grant conditions of this incentive plan and is obtained and registered in batches by the incentive objects after meeting the corresponding vesting conditions.
  • "Incentive Objects" refers to the company's directors, senior management, core management personnel, key employees, and other individuals deemed necessary for incentive by the board of directors who receive restricted stock according to this incentive plan.
  • "Grant Date" refers to the date on which the company grants restricted stock to the incentive objects, which must be a trading day.
  • "Grant Price" refers to the price per share of restricted stock granted to the incentive objects.
  • "Company Law" refers to the Company Law of the People's Republic of China.
  • "Securities Law" refers to the Securities Law of the People's Republic of China.
  • "Management Measures" refers to the Management Measures for Equity Incentives of Listed Companies.
  • "Listing Rules" refers to the Listing Rules for the Growth Enterprise Market of Shenzhen Stock Exchange.
  • "Self-Regulatory Guidelines No. 1" refers to the Self-Regulatory Guidelines No. 1 for Listed Companies on the Growth Enterprise Market of Shenzhen Stock Exchange.
  • "Articles of Association" refers to the current effective Articles of Association of Shandong Keyuan Pharmaceutical Co., Ltd.
  • "CSRC" refers to the China Securities Regulatory Commission.
  • "SZSE" refers to the Shenzhen Stock Exchange.
  • "Yuan, Ten Thousand Yuan" refers to Renminbi Yuan, Ten Thousand Yuan.

Legal Opinion

Beijing Deheng (Jinan) Law Firm has been entrusted by Shandong Keyuan Pharmaceutical Co., Ltd. to act as a special legal advisor for this incentive plan. In accordance with the Company Law, Securities Law, Management Measures, Listing Rules, Self-Regulatory Guidelines No. 1, and other relevant laws, regulations, and normative documents, and following the recognized business standards, ethical norms, and diligent spirit of the legal profession, we have verified the relevant facts of this incentive plan's reserved grant and hereby issue this legal opinion.

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Sign in to read moreSee Pro pricing